|
|
|
|
This is the official website for the Olmesartan Products Resolution Program, a private settlement program established for the purpose of resolving Claims related to Olmesartan Products, including those pending in these proceedings as of August 1, 2017:
1. In Re: Benicar (Olmesartan) Products Liability Litigation, MDL No. 2606 (the “MDL”), a federal multi-district litigation venued in the United States District Court for the District of New Jersey;
2. Any other federal court proceedings, either pending in that court or awaiting transfer to the MDL;
3. In re: Benicar (Olmesartan Medoxomil), Case No. 299, venued in the Superior Court of New Jersey, Law Division: Atlantic County; and
4. Any and all other state court proceedings.
|
|
| Important Dates |
|
MDL and New Jersey Coordinating Court Census Order Deadline
August 25, 2017
Supplemental Census for Registered Unfiled Claims Deadline
December 1, 2017
Opt In Deadline
May 15, 2018
Effective Date
11:59 PM ET on the 14th day following the last Opt In Deadline attributable to any Eligible Enrollee
|
|
|
Claimants with Claims that have not yet been filed in any jurisdiction are also eligible to participate in the Program as set out in the Settlement Agreement.
|
|
ENROLLMENT: ENROLLMENT IS NOW OPEN. You may now enroll claimants in the Olmesartan Products Resolution Program. Because the Master Settlement Agreement has been amended, all claimants must use the revised Enrollment documents when completing their Opt In Packages. Any Enrollment materials submitted before 3/30/18 are not valid, and the claimant must fill out and submit the new documents. Log into your Portal to begin the Enrollment process for your clients. The deadline for submitting all of your Opt In Package materials is May 15, 2018.